头孢曲松在患脑膜炎儿科患者中的药代动力学。
Pharmacokinetics of ceftriaxone in pediatric patients with meningitis.
作者信息
Steele R W, Eyre L B, Bradsher R W, Weinfeld R E, Patel I H, Spicehandler J
出版信息
Antimicrob Agents Chemother. 1983 Feb;23(2):191-4. doi: 10.1128/AAC.23.2.191.
Abstract
Pharmacokinetics of ceftriaxone after a single dose of 50 or 75 mg/kg were determined in 30 pediatric patients with bacterial meningitis. Data for doses of 50 and 75 mg/kg, respectively, were as follows (mean +/- standard deviation): maximum plasma concentrations, 230 +/- 64 and 295 +/- 76 mug/ml; elimination rate constant, 0.14 +/- 0.06 and 0.14 +/- 0.04 h(-1); harmonic elimination half-life, 5.8 +/- 2.8 and 5.4 +/- 2.1 h; plasma clearance, 51 +/- 24 and 55 +/- 18 ml/h per kg; volume of distribution, 382 +/- 129 and 387 +/- 56 ml/kg; mean concentration in cerebrospinal fluid 1 to 6 h after infusion, 5.4 and 6.4 mug/ml. A dosage schedule of 50 mg/kg every 12 h for bacterial meningitis caused by susceptible organisms is suggested for pediatric patients over 7 days of age.
摘要
在30例细菌性脑膜炎患儿中测定了单次给予50或75mg/kg剂量头孢曲松后的药代动力学。50mg/kg和75mg/kg剂量的数据分别如下（平均值±标准差）：血浆最大浓度，230±64和295±76μg/ml；消除速率常数，0.14±0.06和0.14±0.04h⁻¹；调和消除半衰期，5.8±2.8和5.4±2.1h；血浆清除率，51±24和55±18ml/（h·kg）；分布容积，382±129和387±56ml/kg；输注后1至6小时脑脊液中的平均浓度，5.4和6.4μg/ml。建议7日龄以上的儿科患者对于由敏感菌引起的细菌性脑膜炎采用每12小时50mg/kg的给药方案。
相似文献
1
Pharmacokinetics of ceftriaxone in pediatric patients with meningitis.头孢曲松在患脑膜炎儿科患者中的药代动力学。
Antimicrob Agents Chemother. 1983 Feb;23(2):191-4. doi: 10.1128/AAC.23.2.191.
2
Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis.头孢曲松治疗小儿细菌性脑膜炎的药代动力学及脑脊液杀菌活性
Antimicrob Agents Chemother. 1982 Oct;22(4):622-7. doi: 10.1128/AAC.22.4.622.
3
Pharmacokinetics of ceftriaxone in neonates and infants with meningitis.头孢曲松在患脑膜炎的新生儿和婴儿中的药代动力学。
J Pediatr. 1984 Sep;105(3):475-81. doi: 10.1016/s0022-3476(84)80032-3.
4
[Pharmacokinetics of ceftriaxone in blood and ventricular cerebrospinal fluid in children with ventriculitis].
Bol Med Hosp Infant Mex. 1984 Jun;41(6):313-7.
5
Single-dose plasma and cerebrospinal fluid pharmacokinetics of ceftriaxone in infants and children.
Clin Pharm. 1983 Nov-Dec;2(6):558-63.
6
Single-dose pharmacokinetics of ceftriaxone in infants and young children.头孢曲松在婴幼儿中的单剂量药代动力学。
Antimicrob Agents Chemother. 1982 Feb;21(2):248-53. doi: 10.1128/AAC.21.2.248.
7
Ceftriaxone pharmacokinetics in newborn infants.新生儿中头孢曲松的药代动力学
Antimicrob Agents Chemother. 1983 Feb;23(2):341-3. doi: 10.1128/AAC.23.2.341.
8
Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.头孢噻肟和去乙酰头孢噻肟在患脑膜炎婴幼儿及儿童中的药代动力学
Antimicrob Agents Chemother. 1985 Dec;28(6):791-5. doi: 10.1128/AAC.28.6.791.
9
Comparison of ceftriaxone with standard therapy for bacterial meningitis.头孢曲松与细菌性脑膜炎标准疗法的比较。
J Pediatr. 1983 Jul;103(1):138-41. doi: 10.1016/s0022-3476(83)80801-4.
10
[Treatment of purulent meningitis with ceftriaxone].
Wien Med Wochenschr Suppl. 1985;87:12-6.
引用本文的文献
1
Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia.每日两次1克头孢曲松与每日一次2克头孢曲松治疗吸入性肺炎的有效性和安全性的回顾性比较
Antibiotics (Basel). 2022 Jul 22;11(8):983. doi: 10.3390/antibiotics11080983.
2
Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.目前的头孢曲松剂量推荐方案适用于大多数危重症儿童：一项群体药代动力学建模和模拟研究的结果。
Clin Pharmacokinet. 2021 Oct;60(10):1361-1372. doi: 10.1007/s40262-021-01035-9. Epub 2021 May 26.
3
Variability in Ceftriaxone Dosing Across 32 US Acute Care Children's Hospitals.32 家美国急性护理儿童医院头孢曲松剂量的变异性。
J Pediatric Infect Dis Soc. 2021 May 28;10(5):677-681. doi: 10.1093/jpids/piab004.
4
Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis.基于发育群体药代动力学-药效学分析的婴儿头孢曲松最佳给药剂量
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01412-20.
5
Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children.头孢曲松加阿维巴坦在结核分枝杆菌细胞内中空纤维模型中的评价：对儿童播散性和脑膜结核治疗的影响。
Pediatr Infect Dis J. 2020 Dec;39(12):1092-1100. doi: 10.1097/INF.0000000000002857.
6
Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation.抗生素耐药性对埃塞俄比亚肺炎球菌病治疗的影响：基于代理的建模模拟。
Am J Trop Med Hyg. 2019 Nov;101(5):1042-1053. doi: 10.4269/ajtmh.18-0930.
7
Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions.将头孢曲松用于非肠道给药以增强吸收，作为替代注射溶液的方法。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01170-18. Print 2018 Dec.
8
Validation of a Dried Blood Spot Ceftriaxone Assay in Papua New Guinean Children with Severe Bacterial Infections.验证干血斑头孢曲松检测法在巴布亚新几内亚重症细菌性感染患儿中的应用。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.00940-18. Print 2018 Oct.
9
Effects of ceftriaxone on hydrocodone seeking behavior and glial glutamate transporters in P rats.头孢曲松对P大鼠中氢可酮觅药行为和胶质谷氨酸转运体的影响。
Behav Brain Res. 2018 Jul 16;347:368-376. doi: 10.1016/j.bbr.2018.03.043. Epub 2018 Mar 28.
10
Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.基于药代动力学-药效学的抗菌药物剂量优化用于治疗新生儿革兰氏阴性菌感染的证据评估。
Indian J Med Res. 2017 Mar;145(3):299-316. doi: 10.4103/ijmr.IJMR_723_15.
本文引用的文献
1
Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.广谱头孢菌素Ro 13-9904的药代动力学
Antimicrob Agents Chemother. 1980 Aug;18(2):240-2. doi: 10.1128/AAC.18.2.240.
2
Treatment of purulent meningitis with a new cephalosporin-Rocephin (Ro 13-9904). Clinical, bacteriological and pharmacological observations in 24 cases.用新型头孢菌素——罗氏芬（Ro 13 - 9904）治疗化脓性脑膜炎。24例临床、细菌学及药理学观察
Chemotherapy. 1981;27 Suppl 1:57-61. doi: 10.1159/000238030.
3
Ceftriaxone (Ro 13-9904) therapy of serious infection.头孢曲松（Ro 13 - 9904）治疗严重感染。
Antimicrob Agents Chemother. 1982 Jul;22(1):36-42. doi: 10.1128/AAC.22.1.36.
4
Ceftriaxone: in vitro studies and clinical evaluation.头孢曲松：体外研究与临床评估。
Antimicrob Agents Chemother. 1982 Jul;22(1):1-9. doi: 10.1128/AAC.22.1.1.
5
Single-dose pharmacokinetics of ceftriaxone in infants and young children.头孢曲松在婴幼儿中的单剂量药代动力学。
Antimicrob Agents Chemother. 1982 Feb;21(2):248-53. doi: 10.1128/AAC.21.2.248.
6
Pharmacokinetics of ceftriaxone in humans.头孢曲松在人体内的药代动力学。
Antimicrob Agents Chemother. 1981 Nov;20(5):634-41. doi: 10.1128/AAC.20.5.634.
7
In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.新型广谱半合成头孢菌素头孢曲松（Ro 13-9904）的体内活性
Antimicrob Agents Chemother. 1981 Aug;20(2):159-67. doi: 10.1128/AAC.20.2.159.
8
Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.羟羧氧酰胺菌素、头孢噻肟、头孢哌酮和头孢曲松在实验性细菌性脑膜炎中的药代动力学及细菌学疗效
J Infect Dis. 1981 Feb;143(2):156-63. doi: 10.1093/infdis/143.2.156.
9
In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.儿科患者革兰氏阴性杆菌对羟羧氧酰胺菌素、头孢噻肟、Ro 13-9904及其他头孢菌素的体外敏感性
Antimicrob Agents Chemother. 1980 Sep;18(3):476-9. doi: 10.1128/AAC.18.3.476.
10
Simplified, accurate method for antibiotic assay of clinical specimens.临床标本抗生素检测的简化、准确方法。
Appl Microbiol. 1966 Mar;14(2):170-7. doi: 10.1128/am.14.2.170-177.1966.
Zotero 插件